相关实验视频
Updated: May 2, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.2K
临床实施失效模式和影响分析,用于妇科高剂量率支架疗法
1Department of Medical Engineering, Peking Union Medical College Hospital, Beijing, China.
Journal of contemporary brachytherapy
|April 8, 2024
概括
失败模式和效应分析 (FMEA) 确定了妇科高剂量率 (HDR) 支架疗法的高风险失败. 这种风险评估通过确定改善质量管理的领域来提高患者安全.
科学领域:
- 医学物理 医学物理
- 辐射瘤学 辐射瘤学
- 质量管理质量管理.
背景情况:
- 妇科高剂量率 (HDR) 支臂疗法是一种复杂的程序,需要对细节的细致关注.
- 潜在的故障模式可能会损害治疗疗效和患者安全.
研究的目的:
- 利用故障模式和效应分析 (FMEA) 来识别和评估妇科HDR支架疗法途径中的故障模式.
- 根据严重程度,发生和可检测性来评分已识别的故障模式,以优先考虑风险.
主要方法:
- 一个多学科的团队绘制了妇科的HDR支臂疗法过程,确定了潜在的故障模式 (FMs).
- 用发生率 (O),可检测性 (D) 和严重性 (S) 来计算风险优先级数字 (RPN) 来评分FM.
- 断层树分析 (FTA) 用于高风险的FM (RPN> 100或严重程度> 8) 确定根源原因并优化流程.
主要成果:
- 这项研究在妇科HDR支臂疗法途径的5个子过程和30个步骤中确定了57个FM.
- 确定了12种高风险的FM,其中最严重的是在治疗期间风险器官的变化 (RPN = 245.7).
- 最常见的FM是患者转移期间的应用器转移.
结论:
- FMEA是一个有价值的前性工具,可以在出现故障之前识别甲治疗中的高风险步骤.
- 实施FMEA可以导致制定预防措施,并加强整体质量管理系统.
- 这种系统的方法对于改善妇科HDR支臂治疗中的患者安全至关重要.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:28Dosage Regimens: Designs and Approaches
600
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
01:19Dosage Interval and Administration Route: Determination Methods
564
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
564
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
342
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
342
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97